Sorry, you need to enable JavaScript to visit this website.
Home Science Areas of Focus Internal Medicine

Despite fewer people smoking and effective therapies for hypertension and high cholesterol, cardiovascular disease (CVD) remains the number one cause of death worldwide.1

This epidemic is driven by demographic factors like an aging population, decreasing mortality from other factors (such as infectious disease), and rising rates of obesity—which can drive the progression of metabolic diseases, such as Type 2 diabetes, and lead to the “metabolic syndrome,” a constellation of risk factors that increase an individual’s risk for heart disease and other health problems.2-6

We believe that a comprehensive program is needed to address cardiometabolic disease and the underlying biology responsible for its onset and progression.

Today, we’re focused on investigating the metabolic abnormalities that increase the likelihood of cardiometabolic diseases; working to develop potential therapies for these diseases, which are driven by an abnormal metabolic state; and seeking ways to protect the heart itself, by trying to alter the way it responds to this dysregulated metabolic environment.

This includes more potential therapies targeted to specific metabolic pathways in the body, as well as therapies that are a combination of two or more drugs, which could bring additional benefits to patients.

Our early discovery efforts are focused on obesity, type 2 diabetes, insulin resistance, non-alcoholic fatty liver disease/non-alcoholic steatohepatitis (NASH), and metabolic conditions such as cachexia, a form of unintentional weight loss and muscle-wasting often experienced with cancer and other serious illnesses.

Learn about our dedication to research and collaboration across healthcare in support of patients impacted by cardiometabolic disease.

Our Centers for Therapeutic Innovation collaborates with academic institutions and investigators to push forward great science, using the depth and breadth of the Pfizer enterprise to accelerate concepts into viable therapies with breakthrough potential for patients.

Find Out More About CTI

Revolutionary medicines enable us to enrich and extend life for people suffering from all types of diseases. 

Rare Disease
View All Rare Disease

Explore all of our disease and condition-related resources to learn more about your diagnosis and treatment options. 

Gene Therapy
Duchenne Muscular Dystrophy 
Gaucher Disease
Growth Hormone Deficiency 
Sickle Cell 
Transthyretin Amyloidosis 

Internal Medicine
View All Internal Medicine

We’re developing therapies to treat, slow, or prevent disease progression and improve the quality of life for patients with obesity, type 2 diabetes, and cardiovascular and kidney diseases. 

Inflammation & Immunology
View All Inflammation & Immunology

We look for treatments that provide more than just symptom relief, in order to address the root cause of chronic inflammatory diseases at a molecular level

View All Vaccines

Vaccines are the single most important innovation in the science of health to significantly reduce the threat of diseases that were once widespread and oftentimes fatal. 

Pipeline & Clinical Trials 

View All Oncology

Cancer treatment needs to be transformed across the entire landscape to significantly improve the lives of cancer patients worldwide.

Biology into medicine
Global Impact

Anti Infectives
View All Anti Infectives

Anti-infectives are medicines that work to prevent or treat infections, including antibacterials, antivirals, antifungals, and antiparasitic medications. 

Antimicrobial Resistance 
AMR Prevention 
Antimicrobial Surveillance 
Antimicrobial Stewardship 
Our Commitment as a Global Leader 
Environmental Protection 

The medicines available today have taken an average of 12 years to develop. With dedication, creativity, and science we can significantly cut that time.

  • 00Phase 1
  • 00Phase 2
  • 00Phase 3
  • 00Registration
  • 00Total

Learn more about the process of joining a clinical trial and find a trial near you.

Media Name: Kendra_Bence_300x170px.jpg

Executive Director, Metabolism


Senior Vice President and Chief Scientific Officer, Internal Medicine Research Unit

Media Name: bei_zhang_300x170.jpg

Vice President, Metabolic Research

We proudly partner with thousands of study sites and tens of thousands of trial participants around the world. It’s these clinical trials that lead to life-changing medicines.

Go to Pfizer Clinical Trials Site